Next Article in Journal
HIV DNA Vaccine: Stepwise Improvements Make a Difference
Next Article in Special Issue
Caspase-1 Dependent IL-1β Secretion and Antigen-Specific T-Cell Activation by the Novel Adjuvant, PCEP
Previous Article in Journal / Special Issue
Vaccine Potentiation by Combination Adjuvants
Article Menu

Export Article

Open AccessReview
Vaccines 2014, 2(2), 323-353; doi:10.3390/vaccines2020323

Immune Adjuvant Effect of Molecularly-defined Toll-Like Receptor Ligands

Section of Infectious Diseases, Department of Medicine, Boston University School of Medicine, Boston, MA 02118, USA
*
Author to whom correspondence should be addressed.
Received: 11 February 2014 / Revised: 27 March 2014 / Accepted: 28 March 2014 / Published: 25 April 2014
(This article belongs to the Special Issue Vaccine Adjuvants)
View Full-Text   |   Download PDF [887 KB, uploaded 25 April 2014]   |  

Abstract

Vaccine efficacy is optimized by addition of immune adjuvants. However, although adjuvants have been used for over a century, to date, only few adjuvants are approved for human use, mostly aimed at improving vaccine efficacy and antigen-specific protective antibody production. The mechanism of action of immune adjuvants is diverse, depending on their chemical and molecular nature, ranging from non-specific effects (i.e., antigen depot at the immunization site) to specific activation of immune cells leading to improved host innate and adaptive responses. Although the detailed molecular mechanism of action of many adjuvants is still elusive, the discovery of Toll-like receptors (TLRs) has provided new critical information on immunostimulatory effect of numerous bacterial components that engage TLRs. These ligands have been shown to improve both the quality and the quantity of host adaptive immune responses when used in vaccine formulations targeted to infectious diseases and cancer that require both humoral and cell-mediated immunity. The potential of such TLR adjuvants in improving the design and the outcomes of several vaccines is continuously evolving, as new agonists are discovered and tested in experimental and clinical models of vaccination. In this review, a summary of the recent progress in development of TLR adjuvants is presented. View Full-Text
Keywords: TLR; vaccine adjuvant; immune response; microbial pathogens; cancer TLR; vaccine adjuvant; immune response; microbial pathogens; cancer
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Toussi, D.N.; Massari, P. Immune Adjuvant Effect of Molecularly-defined Toll-Like Receptor Ligands. Vaccines 2014, 2, 323-353.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Vaccines EISSN 2076-393X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top